Allergan Again Pressures FDA On Restasis Generics
Allergan PLC is continuing its push to keep a generic version of the dry-eye blockbuster Restasis off the market by submitting at least its third citizen petition to the U.S. Food...To view the full article, register now.
Already a subscriber? Click here to view full article